Back to Search
TRISHA CARDILLO, MD
MD
Psychiatry Physician
NPI: 1881222800IndividualAccepts Medicare
Specialties, Licenses & Credentials
Psychiatry PhysicianPrimary
Psychiatry & Neurology — Psychiatry
Code: 2084P0800X
ME166802(FL)
CMS Specialties
PrimaryPSYCHIATRY
Education
OTHER
Class of 2020
Research & Publications (20)
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma.
PMID 19372261·Blood·2009
7-preclinical
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
PMID 18941114·Blood·2009
4-observational
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.
PMID 18922911·Cancer Res·2008
7-preclinical
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
PMID 18559529·Cancer Res·2008
7-preclinical
Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.
PMID 18025153·Blood·2008
8-other
Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy.
PMID 18939816·J Med Chem·2008
8-other
Yeast N(alpha)-terminal acetyltransferases are associated with ribosomes.
PMID 17541948·J Cell Biochem·2008
4-observational
CD74: a new candidate target for the immunotherapy of B-cell neoplasms.
PMID 17875789·Clin Cancer Res·2007
6-review
New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.
PMID 16344318·J Clin Oncol·2006
8-other
Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
PMID 17000696·Clin Cancer Res·2006
4-observational
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting.
PMID 16636283·Proc Natl Acad Sci U S A·2006
7-preclinical
Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
PMID 16033844·Clin Cancer Res·2005
7-preclinical
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody.
PMID 16258537·Nat Med·2005
4-observational
Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells.
PMID 16203811·Clin Cancer Res·2005
7-preclinical
Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
PMID 16203810·Clin Cancer Res·2005
7-preclinical
Identification of a Mu-9 (anti-colon-specific antigen-p)-reactive peptide having homology to CA125 (MUC16).
PMID 15870874·Int J Oncol·2005
8-other
CD74 is expressed by multiple myeloma and is a promising target for therapy.
PMID 15475450·Clin Cancer Res·2004
7-preclinical
Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer.
PMID 15548711·Cancer Res·2004
8-other
Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies.
PMID 15297317·Blood·2004
7-preclinical
Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
PMID 15161715·Clin Cancer Res·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 5635 SUPERIOR DR
LAKELAND, FL 33805 - Phone
- (404) 644-3865
Quick Facts
- NPI
- 1881222800
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 2
- Years in Practice
- 6
- Publications
- 20
Are you this provider?
Claim Your Profile